Overview

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Status:
Withdrawn

Trial end date:
2019-07-01

Target enrollment:

Participant gender:

Summary

This research study is being down to find what, effects, good and/or bad, adding Pembrolizumab to standard chemotherapy mFOLFOX before and after surgery have on the patient and the patient's cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Weijing Sun, MD, FACP

Treatments:

Pembrolizumab